MON-645 Metabolic Chorea: A Case Report
Abstract
Abstract Disclosure: M. Vasquez Cayoja: None. R. Pujala Melero: None. J. Garnica Zenteno: None. J. Zubieta Caceres: None. Metabolic Chorea: A Case Report Introduction Hyperglycemic chorea is a rare complication in diabetic patients, associated with non-ketotic hyperglycemia, and is characterized by involuntary movements such as hemichorea or hemiballismus. It is usually accompanied by basal ganglia alterations on neuroimaging. We present the case of a 59-year-old female patient with type 2 diabetes under follow-up for 20 years and a history of hypertension, who experienced renal function deterioration leading to the modification of her treatment with NPH insulin and empagliflozin. Case Report: In November 2024, the patient presented with a two-day history of holocranial headache of mild to moderate intensity, accompanied by asthenia, adynamia, and blurred vision. Over the last 12 hours, she developed irregular, brief, bilateral involuntary movements in the upper and lower limbs and trunk, along with gait instability, prompting her admission to the emergency department. Physical examination: The patient was alert and oriented to person, place, and time, with no signs of meningeal irritation. She exhibited bilateral choreiform movements triggered by motor stimulation. Laboratory on admission: • Glucose: 339 mg/dL • Hematocrit: 30% | Hemoglobin: 10 g/dL | WBC: 8,300/mm³ (76% neutrophils) • Creatinine: 4.6 mg/dL | Urea: 160 mg/dL | ASTO Negative | Na: 135 mEq/L | K: 6.5 mEq/L |…
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.